UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 163 filers reported holding UNIQURE NV in Q3 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $414,741 | +637963.1% | 828,201 | +14460.5% | 1.06% | – |
Q2 2023 | $65 | -43.5% | 5,688 | 0.0% | 0.00% | -100.0% |
Q1 2023 | $115 | -10.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $129 | -99.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $107,000 | +0.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $106,000 | +2.9% | 5,688 | 0.0% | 0.00% | – |
Q1 2022 | $103,000 | -12.7% | 5,688 | 0.0% | 0.00% | – |
Q4 2021 | $118,000 | -35.2% | 5,688 | 0.0% | 0.00% | -100.0% |
Q3 2021 | $182,000 | +4.0% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $175,000 | -8.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $192,000 | -6.8% | 5,688 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $206,000 | -1.4% | 5,688 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $209,000 | -18.4% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $256,000 | -5.2% | 5,688 | 0.0% | 0.00% | -50.0% |
Q1 2020 | $270,000 | -31.3% | 5,688 | +3.7% | 0.00% | 0.0% |
Q4 2019 | $393,000 | +81.9% | 5,487 | 0.0% | 0.00% | +100.0% |
Q3 2019 | $216,000 | – | 5,487 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |